COGNICURRENT

Jan 13 • 05:11 UTC • 🇨🇳 China • South China Morning Post

China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs

China’s SciNeuro Pharmaceuticals has partnered with Swiss firm Novartis in a $1.7 billion deal to develop drugs for Alzheimer’s disease.

#alzheimer's #sci-neuro #novartis #pharmaceuticals #china

Read Original Back to Feed

📡 Similar Coverage

🇨🇳 China Jan 8 • 00:30 UTC

Chinese drug makers strike a record US$136 billion in out-licensing deals in 2025

South China Morning Post

🇨🇳 China Feb 6 • 09:00 UTC

Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships

South China Morning Post

🇧🇷 Brazil Feb 18 • 16:01 UTC

Beijing supports progress in brain implants to rival Elon Musk's Neuralink

Folha (PT)

🇦🇷 Argentina Feb 4 • 10:31 UTC

A new era against Alzheimer's: effective drugs and early diagnosis promise a future without dementia

Clarin (ES)

🇨🇳 China Feb 11 • 06:00 UTC

Capital injection: China backs AI drug makers in self-reliance drive

South China Morning Post

🇨🇳 China Jan 2 • 22:00 UTC

China’s biopharma sector ‘in prime position to challenge US leadership’

South China Morning Post